ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

The atrial fibrillation market, in particular, presents significant growth opportunities for Boston Scientific. With the potential expansion of indications for the Watchman device, the company is ...

today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study ...

The SURPASS (Safety and Efficacy of the WATCHMAN FLX Device in Patients With Non‐Valvular Atrial Fibrillation) registry is an analysis of patients who underwent LAAO with the WATCHMAN FLX device as ...

New research shows that cryoablation is a safe and effective approach to close congenital patent foramen ovale (PFO, a small ...

The odds of complications and early mortality are higher among LAAO recipients with kidney impairment. Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) increase the risks for ...

"The pursuit of an ideal PFO closure method without a residual device is a compelling endeavor. Our aim was to investigate the efficacy and safety of PFO closure using cryoablation without ...

On Nov. 18, the heart failure and transplantation team at Emory University Hospital (EUH) made history, performing the first-ever surgical implantation in the United States of a brand-new type of ...